No Picture
News

GenMark Diagnostics Announces Closing of $80 Million Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

CARLSBAD, Calif., May 11, 2020 (GLOBE NEWSWIRE) — GenMark Diagnostics, Inc. (NASDAQ: GNMK) (“GenMark” or the “Company”), a molecular diagnostics company focused on developing and commercializing multiplex molecular diagnostic solutions designed to e… […]

No Picture
News

Halozyme Reports First Quarter 2020 Results

– DARZALEX FASPRO(TM) Utilizing ENHANZE® Technology Receives U.S. FDA Approval with Subcutaneous Administration Time of 3 – 5 Minutes and Lower Rate of Administration-related Reactions When Compared with IV DARZALEX® — Positive CHMP Opinion Recommendi… […]